Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme.
Authors / Editors
Research Areas
No matching items found.
Publication Details
Output type: Journal article
Author list: Kase, Minajeva, Niinepuu, Kase, Vardja, Asser, Jaal
Publisher: Sciendo
Publication year: 2013
Volume number: 47
Issue number: 4
Start page: 405
End page: 10
Number of pages: -394
ISSN: 1318-2099
eISSN: 1581-3207
Languages: English-Great Britain (EN-GB)
Unpaywall Data
Open access status: gold
Full text URL: https://sciendo.com/pdf/10.2478/raon-2013-0055
Abstract
BACKGROUND\nThe aim of the study was to assess the impact of CD133-positive (CD133+) cancer stem cell proportions on treatment results of glioblastoma multiforme (GBM) patients.\nPATIENTS AND METHODS\nPatients with GBM (n = 42) received postoperative radiotherapy (± chemotherapy). Surgically excised GBM tissue sections were immunohistochemically examined for CD133 expression. The proportions of CD133+ GBM cells were determined (%). The proportion of CD133+ GBM stem cells was established by 2 independent researchers whose results were in good accordance (R = 0.8, p < 0.01). Additionally, CD133 expression levels were correlated with patients overall survival.\nRESULTS\nThe proportion of CD133+ cells varied between patients, being from 0.5% to 82%. Mean and median proportions of CD133+ cells of the entire study group were 33% ± 24% (mean ± SD) and 28%, respectively. Clinical data do not support the association between higher proportion of stem cells and the aggressiveness of GBM. Median survival time of the study group was 10.0 months (95% CI 9.0-11.0). The survival time clearly depended on the proportion of CD133+ cells (log rank test, p = 0.02). Median survival times for patients with low (< median) and high (≥ median) proportion of CD133+ cells were 9.0 months (95% CI 7.6-10.5) and 12.0 months (95% CI 9.3-14.7), respectively. In multivariate analysis, the proportion of CD133+ cells emerged as a significant independent predictor for longer overall survival (HR 2.0, 95% CI 1.0-3.8, p = 0.04).\nCONCLUSIONS\nIn patients with higher stem cell proportion, significantly longer survival times after postoperative radiotherapy were achieved. Underlying reasons and possible higher sensitivity of GBM stem cells to fractionated radio-therapy should be clarified in further studies.
Keywords
No matching items found.
Documents
No matching items found.
